The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
TSGA IPA: The Australian Aquatic Animal Health And Vaccine Centre: First Phase To Establish Atlantic Salmon Biosecure Fish Facility Capabilities And Develop Strategy For An Australian Centre Of Excellence
Funder
Fisheries Research and Development Corporation
Funding Amount
$1,694,600.00
Summary
Commercial in confidence. To know more about this project please contact FRDC. Objectives: Commercial in confidence
Production Of Antibodies Against Toxins Involved In Ciguatera Fish Poisoning
Funder
Fisheries Research and Development Corporation
Funding Amount
$87,050.00
Summary
Objectives: 1. Develop method of detection of ciguatoxin (CTX) to extract & purify sufficient CTX to service requirements of program. 2. Develop an en enzyme imunassay for measuring anti-CTX production. 3. Develop method of schedule immunisation to allow production of monoclonal antibodies
SCRC: Seafood CRC Participant Sponsorship To 2011 National Seafood Industry Leadership Program
Funder
Fisheries Research and Development Corporation
Summary
The CRC is all about capacity building within the CRC participants and the FRDC Seafood Leadership Program enables the opportunity to invest in people who are keen to show their leadership potential. Investing in Leadership, and the associated networks and cross stakeholder understanding is seen as vitally important for all sectors to be able to contribute to debate, drive change and address challenges in order to enable the Seafood CRC and the industry to reach its potential.
FRDC has obtained Board approval FRDC Board Meeting # 194, 24 November 2022) to become a member of CRC SAAFE and investment up to $1.0 million. This project is needed to manage the FRDC investment that will be comprised of investments seafood related projects. Conducting projects within CRC SAAFE will provide linkages to additional resources, expertise and knowledge sharing that will improve project outputs and foster national collaboration in addition to that currently provided by the FRDC. Th ....FRDC has obtained Board approval FRDC Board Meeting # 194, 24 November 2022) to become a member of CRC SAAFE and investment up to $1.0 million. This project is needed to manage the FRDC investment that will be comprised of investments seafood related projects. Conducting projects within CRC SAAFE will provide linkages to additional resources, expertise and knowledge sharing that will improve project outputs and foster national collaboration in addition to that currently provided by the FRDC. This will include the research and industry participants that are partners of CRC SAAFE. Objectives: 1. Best practice AMR mitigation and management in the seafood industry and the aquatic environment. 2. Improved biosecurity and animal welfare through development of vaccines to minimise use of antibiotics. Read moreRead less
The vision we rely on every day to read and recognise faces depends upon the health of the central portion of our retina, the macula. Age-related Macular Degeneration (AMD) is the leading cause of blindness in Australia and the western world. Researchers at the Australian National University are collaborating to bring a new test for AMD severity to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them manage treatment.
Development Of Vaccines And Rapid Diagnostic Monoclonal Antibodies Against Micro-organisms Associated With Diseases Of Wild And Cultured Finfish And Shellfish
Funder
Fisheries Research and Development Corporation
Funding Amount
$166,772.00
Summary
Objectives: 1. Identification and characterisation of species-specific antigenic determinants that are heat-stable components of the lipopolysaccharide (LPS) on pathogenic gram-negative bacteria. 2. Prepare a library of species and genus-specific monoclonal antibodies against the heat-stable LPS components of pathogenic gram-negative bacteria 3. Select appropriate hybridomas, that produce high affinity monoclonal antibodies, for transfer to strategic companies 4. Complete t ....Objectives: 1. Identification and characterisation of species-specific antigenic determinants that are heat-stable components of the lipopolysaccharide (LPS) on pathogenic gram-negative bacteria. 2. Prepare a library of species and genus-specific monoclonal antibodies against the heat-stable LPS components of pathogenic gram-negative bacteria 3. Select appropriate hybridomas, that produce high affinity monoclonal antibodies, for transfer to strategic companies 4. Complete the testing of specific LPS fragments extracted from one Vibrio species to produce vaccine against all Vibrio pathogens 5. Use the same approach as in (4) to test the genus-specific protection afforded by similar LPS fragrments extracted from additional pathogens, particularly Aeromonas salmonicida 6. Develop and market commercial products for use rapid diagnoses and in research of infections of wild and cultured fish and shellfish Read moreRead less
Roles Of Impaired Apoptosis And Differentiation In Tumourigenesis And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$21,656,910.00
Summary
The ten scientific laboratories in this program have joined forces to investigate two ways in which tumours develop. Both are of particular interest, because they suggest new ways in which cancer might be overcome. Most of our tissues are continually renewed throughout life by production of new cells. Therefore many of the old cells in each tissue must die off to maintain the proper cell numbers. To eliminate cells that are no longer needed or have become damaged, the body has developed a remark ....The ten scientific laboratories in this program have joined forces to investigate two ways in which tumours develop. Both are of particular interest, because they suggest new ways in which cancer might be overcome. Most of our tissues are continually renewed throughout life by production of new cells. Therefore many of the old cells in each tissue must die off to maintain the proper cell numbers. To eliminate cells that are no longer needed or have become damaged, the body has developed a remarkable cell suicide process termed apoptosis. Unfortunately, however, occasionally a random accident to the genes in one of our cells prevents the machinery for apoptosis from being turned on. In that case, the cell will not die when it should and, by continually dividing, it may eventually give rise to a cancer. Since most cancer cells still retain most of the machinery for apoptosis, however, a drug that could switch on this natural cell death machinery would provide a promising new approach to cancer therapy. Identifying and developing such drugs is one major long-term goal of this program. The other focus of our program concerns stem cells. These are rare cells with the remarkable ability to generate an entire tissue. For example, one of our laboratories has identified stem cells that can generate all the cells in the breast. The almost unlimited regenerative capacity of stem cells has a built-in danger. If a stem cell acquires the ability to proliferate excessively, it can go on to form a tumour. Indeed, many cancer researchers now suspect that rare stem cells within a tumour cause its inexorable growth. If tumour growth is maintained by stem cells, it will be essential to develop new forms of therapy that target these rare cancer stem cells rather than merely the bulk of the tumour cells. This is another key long-term goal of our program.Read moreRead less